Zanidatamab (zani) in previously treated HER2+ biliary tract cancer (BTC): Impact on patient-reported pain outcomes in the phase 2b HERIZON-BTC-01 study. Analysis of patients (pts) with unresectable ...
Phase II study of trastuzumab-pkrb plus gedatolisib in patients with HER2-positive metastatic breast cancer who progressed after 2 or more HER2-directed chemotherapies (KM-10A/KCSG BR18-13). This is ...
In today's digital economy, data has become one of the most valuable assets any organization can possess. Yet, for all its abundance, data on its own rarely leads to understanding. The challenge for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results